Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.
Idvynso uniquely offers a two-drug, tenofovir-free, non-INSTI single-tablet regimen intended for switch in stable, suppressed ...
HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...
Health and Me on MSN
US FDA approves Merck’s once-daily combination pill for treating adults with HIV
According to the latest data from UNAIDS, 40.8 million people globally were living with HIV in 2024. Of these, 39.4 million ...
After 48 weeks of treatment, TPN-101 reduced the levels of neurofilament light chain and interleukin 6, both key biomarkers of neurodegeneration and neuroinflammation in PSP. The Food and Drug ...
The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).
MedPage Today on MSN
FDA Approves New Standalone Combo Pill for HIV
Islatravir-doravirine matched alternate regimens in two phase III trials ...
Morning Overview on MSN
FDA approves Merck’s Idvynso combo pill for HIV treatment
The U.S. Food and Drug Administration on April 21, 2026, approved Merck’s Idvynso, a once-daily combination pill for HIV ...
This article and associated images are based on a poster originally authored by Cristina Alli, Chiara Soldati, Ottavia Cecchetti, Monica Bisbocci, Sara Pugliese, Mauro Cerretani, Elisa Beghetto, Marta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results